sinovac®

孩尔来福®
Healive®

A WHO Prequalified Inactivated Hepatitis A Vaccine



30+
Phase Ⅳ Clinical Studies

60 +
Authoritative Articles

>50,000,000
Doses Administrated in the World until 2017

- ***A WHO Prequalified Inactivated Hepatitis A Vaccine***
- ***Sufficient Production Capacity: 20 million doses per year***
- ***Long Product Shelf Life: 42 months***
- ***Completed Product Registration Dossiers***

Brief Introduction of Healive®

[Name of the Medicinal Product]

- Generic Name: Hepatitis A Vaccine (Human Diploid Cell), Inactivated
- Trade Name: Healive®

[Composition and Description]

- Healive®, Inactivated Hepatitis A Vaccine is derived from hepatitis A virus cultured in human diploid cell, followed by harvest, purification, inactivation by formaldehyde and aluminum adsorption. Healive® is a purified sterile suspension.
- Active Ingredient: Inactivated hepatitis A virus antigen.
- Excipients: Aluminum hydroxide, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, and water for injection.

[Target Groups For Vaccination]

- Susceptible people aged over 12 months.

[Therapeutic Indication]

- Healive® can introduce body to generate immunoreactions against hepatitis A virus, and can be used for prevention of infection caused by hepatitis A virus.

[Strength]

- Each package contains 0.5ml or 1.0ml. Single dose of 1.0ml containing 500u is for adult use. Single dose of 0.5ml containing 250u is for junior use.

[Administration and Dosage]

Age Group	*Dosage*	*Number of Doses*
≥ 16 years old	500 u / 1.0 ml	2 (6 months interval)
>1 but < 16 years old	250 u / 0.5 ml	2 (6 months interval)

- Healive® should be administered by intramuscular injection in the deltoid region.

[Contraindications]

- Subjects with known allergic reaction to any component of the vaccine, including excipients, formaldehyde and gentamycin sulfate.

[Storage]

- Store and transport between +2℃ and +8℃, protected from light. Do not freeze.

[Package]

- Pre filled syringe or vial. The package unit is one syringe or one vial.

[Shelf Life]

- 42 months.

No.39, Shangdi Xi Road, Haidian District, Beijing 100085, P.R.China
+86-10-8279 9382 / 9586 info@sinovac.com
www.sinovac.com

sinovac®

益尔来福® Inlive®

Enterovirus Type 71 Vaccine, Inactivated (Vero Cell)

A Leading Preventive Biological Product against Hand, Foot and Mouth Disease caused by EV71 in the World



94.6%
Protective Rate to HFMD caused by EV71

100%
Protective Rate to HFMD of Severe Case and Hospitalization caused by EV71

>10,000
Clinical Trial Subjects

Free
Preservative and Stabilizer

- ***The Leading Manufacturer of EV71 Vaccine in the World***
- ***Production Capacity: 20 million doses per year***
- ***Completed Product Registration Dossiers***

Brief Introduction of Inlive®



[Name of the Medicinal Product]

- Generic Name: Enterovirus Type 71 Vaccine (Vero cell), Inactivated
- Trade Name: Inlive®

[Composition and Description]

- Inlive®, inactivated Enterovirus type 71 vaccine is derived from Enterovirus type71 virus (EV71 H07 Strain) cultured in Vero cells, followed by culture, harvest, inactivation, concentration, purification and aluminum hydroxide adsorption. Inive® is white suspension liquid and easily shaking.
- Active Ingredient: Inactivated EV71 virus antigen
- Excipients: Aluminum hydroxide, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, and water for injection.

[Target Groups For Vaccination]

- Susceptible people aged within 6 months to 3 years old.

[Therapeutic Indication]

- Inlive® can induce body to generate immunoreaction against EV71 virus, and can be used to prevent Hand-Foot-Month Disease (HFMD) caused by EV71 virus. Inlive® cannot be used to prevent HFMD caused by other pathogens (such as CoxA 16 etc.) except EV71.

[Strength]

- Each package contains 0.5ml. Single dose of 0.5ml containing EV71 neutralizing antibody titer no less than 3.0EU.

[Administration and Dosage]

- ADMINISTRATION: Inlive® is for intramuscular injection in the deltoid region. Two doses are in the basic immunization with one month interval.
- DOSAGE: 0.5ml/single dose

[Contraindications]

- (1) People who is allergic to any component of vaccine, including gentamycin sulfate.
- (2) People who suffer from acute diseases, acute paroxysm of any chronic disease, fever.
- (3)People who suffer from serious chronic disease,allergic constitution.

[Storage]

- Store or transport between +2 ℃ and +8 ℃, protected from light.

[Package]

- Pre filled syringe or vial. The package unit is one syringe or one vial.

[Shelf Life]

- 36 months.

No.39, Shangdi Xi Road, Haidian District, Beijing 100085, P.R.China
+86-10-8279 9382 / 9586 info@sinovac.com
www.sinovac.com

sinovac®

ANFLU
安 尔 来 福

A Leading Inactivated Influenza Vaccine in the World



- **Sinovac - The 1st IVS Member from Developing Countries**
- **Completed Influenza Vaccines**
  1. Seasonal Influenza Vaccine
  2. Pandemic Influenza Vaccine (H5N1)
  3. Inactivated H1N1 Influenza Vaccine (Split Virion)
  4. Quadrivalent Influenza Vaccine)- Clinical Trial Phase III
  5. Inactivated H7N9 Influenza Vaccine (Split Virion)- Under Research

16
Phase Ⅳ Clinical Studies

14
Authoritative Articles

>30,000,000
Doses Administrated in the World until 2017

- ***Sufficient Production Capacity: 8 million doses per year***
- ***Completed Product Registration Dossiers***

Brief Introduction of Anflu ®

[Name of the Medicinal Product]

- Generic Name: Influenza Vaccine (Split Virion), Inactivated
- Trade Name: Anflu®

[Composition and Description]

- Anflu® is derived from the influenza virus recommended by WHO, which is cultured in chicken embryo, followed by harvest, inactivation, purification and disruption. Finally, a slightly opalescent suspension with no foreign particles is obtained.

[Target Groups For Vaccination]

- Vaccination is recommended for the susceptible person and those having high risk of associated complications, such as children aged over 6 months, senior citizens, weakling and those who are in influenza epidemic areas.

[Therapeutic Indication]

- Anflu® can introduce body to generate immunoreactions against influenza virus and can be used for prevention of infection caused by influenza virus.

[Strength]

- Each package contains 0.25ml or 0.5ml. Single dose of 0.25ml containing 7.5μg haemagglutinin per type of influenza virus strain is for children aged from 6months to 36 months use. Single dose of 0.5ml containing 15μg haemagglutinin per type of influenza virus strain is for adult and children over 3 years.

[Administration and Dosage]

Age Group	*Dosage*	*Number of Dose(s)*
> 3 years old	0.5 ml	1
≥ 6 months but ≤ 3 years old	0.25 ml	2 (4 weeks interval)

- Anflu® should be administered by intramuscular injection in the deltoid region.

[Contraindications]

- Subjects with known allergic reaction to any component of the vaccine, including excipients, such as eggs, formaldehyde, Triton X-100 and gentamycin sulfate.
- Immunization shall be postponed in patients with febrile illness or acute infection.

[Storage]

- Store and transport between +2℃ and +8℃, protected from light. Do not freeze.

[Package]

- Pre filled syringe or vial. The package unit is one syringe or one vial.

[Shelf Life]

- 12 months.

No.39, Shangdi Xi Road, Haidian District, Beijing 100085, P.R.China
+86-10-8279 9382 / 9586 info@sinovac.com
www.sinovac.com

sinovac®

Provide Chinese Children with Top Quality Vaccines
Provide Children around the World with Vaccines Made in China

About Sinovac

Sinovac Biotech Co., Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines for infectious diseases with significant unmet medical need.

SINOVAC BIOTECH CO., LTD.

+86-10-8279 9382 / 9586

info@sinovac.com

No.39, Shangdi Xi Road, Haidian District, Beijing 100085, P.R.China

www.sinovac.com

WHAT WE CAN DO FOR YOU

Extensive and Top Quality Portfolio and Pipeline Vaccines Products

Commercialized Portfolio

- A WHO Prequalified Inactivated Hepatitis A Vaccine
- A Leading Preventive Biological Product against Hand, Foot and Mouth Disease caused by EV71 in the World
- A Leading Inactivated Influenza Vaccine in the World

Pipeline Vaccines Products

- **PPV23** 23-valent Pneumococcal Polysaccharide Vaccine
- **sIPV** Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strain
- **QIV** Quadrivalent Influenza Vaccine
- **Varicella Vaccine**

Sufficient Production Capacity with Timely and Reliable Vaccines Products Supply

孜尔来福® Healive®

Production Capacity: 20 million doses per year

益尔来福® Inlive®

Production Capacity: 20 million doses per year

ANFLU 安尔来福

Production Capacity: 8 million doses per year

※ 2-8 ℃ Cold Chain logistic with Temperature Monitoring

High-Efficient Communication and Flexible Business Model

Finished Product Distribution
Bulk Product Localization
Technology Transfer
.....

Completed Product Registration Dossiers